Bone disease in HIV infection.

Area of Science:

• Endocrinology
• Infectious Diseases
• Bone Metabolism

Background:

• Highly active anti-retroviral therapy (HAART) has transformed HIV/AIDS management, improving patient longevity.
• Metabolic bone disease, including low bone mineral density (BMD), is a recognized complication associated with HIV infection and its treatment.
• The etiology of reduced BMD in HIV-infected individuals is complex, involving HIV itself, conventional osteoporosis risk factors, and antiretroviral therapy.

Purpose of the Study:

• To review clinical evidence connecting HIV-associated osteoporosis to direct HIV infection and HAART.
• To examine the proposed mechanisms contributing to bone loss in this population.
• To provide recommendations for the pharmacological management of HIV/HAART-related osteoporosis.

Main Methods:

• Literature review of clinical studies and evidence.
• Analysis of purported mechanisms of bone loss.
• Synthesis of current recommendations for osteoporosis management in HIV patients.

Main Results:

• HIV infection and HAART are linked to increased risk of osteoporosis.
• Multiple factors, including direct viral effects and antiretroviral drugs, contribute to bone density loss.
• Specific antiretroviral agents and treatment duration may influence the severity of bone disease.

Conclusions:

• HIV infection should be recognized as an independent risk factor for developing osteoporosis.
• Comprehensive management strategies are needed to address bone health in individuals with HIV/AIDS.
• Further research into targeted therapies for HIV-associated bone disease is warranted.